148 related articles for article (PubMed ID: 26621246)
1. In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
Hoxha M; Buccellati C; Capra V; Garella D; Cena C; Rolando B; Fruttero R; Carnevali S; Sala A; Rovati GE; Bertinaria M
Pharmacol Res; 2016 Jan; 103():132-43. PubMed ID: 26621246
[TBL] [Abstract][Full Text] [Related]
2. Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.
Bertinaria M; Shaikh MA; Buccellati C; Cena C; Rolando B; Lazzarato L; Fruttero R; Gasco A; Hoxha M; Capra V; Sala A; Rovati GE
ChemMedChem; 2012 Sep; 7(9):1647-60. PubMed ID: 22865828
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
Selg E; Buccellati C; Andersson M; Rovati GE; Ezinga M; Sala A; Larsson AK; Ambrosio M; Låstbom L; Capra V; Dahlén B; Ryrfeldt A; Folco GC; Dahlén SE
Br J Pharmacol; 2007 Dec; 152(8):1185-95. PubMed ID: 17965743
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the TP receptor in TNF-α-induced endothelial tissue factor expression.
Del Turco S; Basta G; Lazzerini G; Chancharme L; Lerond L; De Caterina R
Vascul Pharmacol; 2014 Aug; 62(2):49-56. PubMed ID: 24699252
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
6. Role of prostacyclin in the cardiovascular response to thromboxane A2.
Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
8. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition.
Pace-Asciak CR; Reynaud D; Demin P; Aslam R; Sun A
J Pharmacol Exp Ther; 2002 May; 301(2):618-24. PubMed ID: 11961065
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
Chang MC; Chang HH; Chan CP; Chou HY; Chang BE; Yeung SY; Wang TM; Jeng JH
Toxicol Appl Pharmacol; 2012 Sep; 263(3):287-95. PubMed ID: 22789837
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the human prostanoid TPalpha and TPbeta receptor isoforms mediated through activation of the EP(1) and IP receptors.
Walsh MT; Kinsella BT
Br J Pharmacol; 2000 Oct; 131(3):601-9. PubMed ID: 11015313
[TBL] [Abstract][Full Text] [Related]
11. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk.
Rovati GE; Sala A; Capra V; Dahlén SE; Folco G
Trends Pharmacol Sci; 2010 Mar; 31(3):102-7. PubMed ID: 20117851
[TBL] [Abstract][Full Text] [Related]
12. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
[TBL] [Abstract][Full Text] [Related]
16. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
Thomas DW; Mannon RB; Mannon PJ; Latour A; Oliver JA; Hoffman M; Smithies O; Koller BH; Coffman TM
J Clin Invest; 1998 Dec; 102(11):1994-2001. PubMed ID: 9835625
[TBL] [Abstract][Full Text] [Related]
17. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha.
Kinsella BT; O'Mahony DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1997 May; 281(2):957-64. PubMed ID: 9152406
[TBL] [Abstract][Full Text] [Related]
18. Characterization and localization of thromboxane A2 receptor in human and guinea-pig nasal mucosa using radiolabelled (+)-S-145.
Arimura A; Miwa M; Hasegawa H; Kishino J; Notoya M; Yasui K; Komori M; Iwata S
Br J Pharmacol; 1998 Jun; 124(4):795-803. PubMed ID: 9690873
[TBL] [Abstract][Full Text] [Related]
19. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
